GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified March 2014 by University of Maryland
Sponsor:
Information provided by (Responsible Party):
Saranya Chumsri, MD, University of Maryland
ClinicalTrials.gov Identifier:
NCT02095184
First received: March 20, 2014
Last updated: NA
Last verified: March 2014
History: No changes posted
  Purpose

More than three quarter of patients with breast cancer are treated by hormone pills called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone production. This hormone production mostly happens in fat, muscle, and breast tissue in postmenopausal women. The female hormone estrogen is an important hormone for the growth of breast cancer cells. Anastrozole (Arimidex®) and Letrozole (Femara®) are AIs that are approved by the Food and Drug Administration (FDA). They have been used since 2005 to treat women with early stage breast cancer.

When given before surgery (neoadjuvant), both anastrozole and letrozole have been shown to successfully shrink breast cancer tumors in most patients. In over 50% of patients, anastrozole and letrozole when given for about 4 months also helped to improve surgery outcomes. On top of that, whether or not a patient responds to anastrozole and letrozole before surgery can help the doctor decide whether that patient needs additional chemotherapy.

One of the things may influence the level of hormone is body weight. It has been previously shown that postmenopausal women with higher body fat have higher level of female hormone as well as an increased risk of breast cancer. This is likely due to an increase in aromatase activity in the fatty tissue. However, at the current time AIs are used at the same doses in all women with breast cancer no matter whether they have different body weight. Currently, we do not know for certain whether the same doses of AIs work as well in patients with higher body fat compared to patients with less body fat.

The purpose of this study is to see if women with higher body fat respond differently to AI treatment compared to women with lower body fat.


Condition Intervention
Breast Cancer
Drug: Anastrozole
Drug: Letrozole

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors to Evaluate Anti-Proliferative Response in Obese and Overweight Patients

Resource links provided by NLM:


Further study details as provided by University of Maryland:

Primary Outcome Measures:
  • Percent change in proliferative index (Ki67) after treatment with the standard dose anastrozole or letrozole in normal, obese, and overweight patients [ Time Frame: 2-4 weeks ] [ Designated as safety issue: No ]
    Percent change in proliferative index (Ki67) after treatment with the standard dose anastrozole or letrozole in normal, obese, and overweight patients


Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Cohort 1: Normal Weight Anastrozole
Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
Drug: Anastrozole
1 mg daily
Active Comparator: Cohort 2: Overweight Anastrozole
Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
Drug: Anastrozole
1 mg daily
Active Comparator: Cohort 3: Obese
Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
Drug: Anastrozole
1 mg daily
Active Comparator: Cohort 4: Normal Weight Letrozole
Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
Drug: Letrozole
2.5 mg daily
Active Comparator: Cohort 5: Overweight Letrozole
Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
Drug: Letrozole
2.5 mg daily
Active Comparator: Cohort 6: Obese Letrozole
Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
Drug: Letrozole
2.5 mg daily

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female greater than or equal to 18 years.
  2. Histologically confirmed or presumptive or previously defined adenocarcinoma of the breast.
  3. Evidence of hormone sensitivity (estrogen receptor [ER] and/or progesterone receptor [PR] ≥ 1%) of primary tumor tissue.
  4. Human estrogen receptor -2 (HER2) negative in the primary tumor tissue as defined by:

    1. Grade 0 or 1+ staining intensity (on a scale of 0 to 3) by means of IHC analysis OR
    2. Grade 2+ staining intensity by means of immuno-histochemical (IHC) analysis with gene amplification on fluorescence in situ hybridization (FISH) < 2.0 OR
    3. Gene amplification on fluorescence in situ hybridization (FISH) < 2.0.
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
  6. Unresected operable presumptive or previously defined breast cancer stage I-III with primary tumor ≥ 1.0 cm.
  7. Ability to understand and the willingness to sign a written informed consent document.
  8. Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsy.
  9. Patients must have an adequate tumor tissue sample prior to enrollment available for correlative studies as defined below: Core needle biopsy or incisional biopsy samples that can provide ≥ 5 unstained sections of 5 micron thickness. Fine needle aspiration (FNA) sample alone is not sufficient.
  10. Patients must have adequate organ function as defined below:

    1. Total bilirubin within normal institutional limits
    2. aspartate aminotransferase (AST)(SGOT)/alanine aminotransferase (ALT)(SGPT) < 2.5 x institutional upper limit of normal
    3. Creatinine clearance ≥ 10 mL/min/1.73 m2

Exclusion Criteria:

  1. Previous or current systemic malignancy within the past 3 years other than breast cancer or adequately treated cervical carcinoma in situ or basal/squamous carcinoma of the skin.
  2. Patients may not be receiving any other investigational agent.
  3. History of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to anastrozole.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02095184

Locations
United States, Maryland
University of Maryland Greenebaum Cancer Center Not yet recruiting
Baltimore, Maryland, United States, 21201
Contact: Nancy Tait, R.N.    410-328-3546    ntait@umm.edu   
Principal Investigator: Saranya Chumsri, M.D.         
Sponsors and Collaborators
University of Maryland
Investigators
Principal Investigator: Saranya Chumsri, M.D. University of Maryland
  More Information

No publications provided

Responsible Party: Saranya Chumsri, MD, Assistant Professor of Medicine, University of Maryland
ClinicalTrials.gov Identifier: NCT02095184     History of Changes
Other Study ID Numbers: HP-00057786
Study First Received: March 20, 2014
Last Updated: March 20, 2014
Health Authority: United States: Institutional Review Board
United States: Office of Human Research Protections

Keywords provided by University of Maryland:
Breast Cancer
Postmenopausal
Hormone-Receptor Positive

Additional relevant MeSH terms:
Breast Neoplasms
Overweight
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Body Weight
Signs and Symptoms
Letrozole
Anastrozole
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal

ClinicalTrials.gov processed this record on September 18, 2014